Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure

Under Danish law the company can during a reconstrution phase resolve on creditor issues and access certain loans.“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time to use this measure under Danish law to resolve some creditors issues. We consider this step as an additional option to secure the liquidity balance in the short term.”, says Thomas Warthoe CEO of Qlife.

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B62Z3C74 Issuer Name Fidelity China Special Situations PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name FIL Limited City of registered office (if applicable) Hamilton Country of registered office (if applicable) Bermuda 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification

Outokumpu’s Board of Directors’ decisions on the composition of the Board committees at their first meeting

Outokumpu CorporationStock exchange releaseApril 4, 2024 at 4.30 pm EESTOutokumpu’s Board of Directors’ decisions on the composition of the Board committees at their first meeting Outokumpu Oyj’s Board of Directors has at its first meeting appointed two permanent committees, the Audit Committee and the Remuneration Committee, and decided on their composition. To the Audit Committee the Board elected Jyrki Mäki-Kala as the Chairman and Päivi Luostarinen, Petter Söderström and Julia Woodhouse as members. To the Remuneration Committee the Board elected Kari Jordan as the Chairman

Rollover of Director's REPO

4 April 2023   Quantum Blockchain Technologies Plc(“the Company”)     Rollover of Director’s REPO   Following previous announcements made by the Company regarding the rollover of the Sale & Repurchase Agreement (the “REPO”) entered into between the Company’s CEO and Executive Chairman, Professor Francesco Gardin, and MC Strategies AG (“MCS”), the Company has been informed that Professor Gardin and MCS have agreed to amend the repurchase price and the repurchase date of the REPO as follows: · The term of the REPO under which Professor Gardin is to repurchase 5,000,

Nel ASA: Additional USD 41 million in tax credits for manufacturing expansion in Michigan

(April 4, 2024 - Oslo, Norway, Nel, OSE:NEL). Nel has been awarded up to USD 41 million in investment tax credits for its planned manufacturing expansion in Michigan as part of the Qualifying Advanced Energy Project Tax Credit (48C) program.“We continue to see strong support for our efforts to scale our US operations, both within advanced research and efficient manufacturing. The support now received increases the attractiveness of investing in expanding our capacity and capability in the US,” says Nel’s President and CEO, Håkon Volldal. The 48C program is funded by the Inflation

Dignitana’s rights issue fully subscribed

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS WHOLLY OR PARTIALLY SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW. Dignitana AB (publ) ("Dignitana" or the "Company") today, on 4 April 2024, announces the outcome of the rights issue of shares that was announced through a press release on 21 February 2024 (the "Rights

RaySearch to present latest innovations in RayStation, RayCare and RayIntelligence at ISOP and NPC (NAPT)

RaySearch Laboratories AB (publ) will present the latest software innovations at IBA’s International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9. Visit us at RaySearch’s table at ISOP and booth at NPC.The focus during both ISOP and NPC will be on support for proton arcs and robust optimization based on linear energy transfer (LET) and adaptive therapy. Further, new features in RayStation®* 2023B related to proton therapy will be highlighted.

OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™

Stockholm, Sweden – April 4, 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid based treatment for oral pain, announces today that ongoing stability studies for the revised formulation of BupiZenge™ show positive results.Stability studies of BupiZenge™ are ongoing in line with previous communication from the company. The data now obtained shows 3 months of positive results within the desired limits of the specification for the development of the latest formulation. This data complements earlier data and analyzes and confirms the

Resolutions of Outokumpu’s Annual General Meeting 2024

Outokumpu CorporationStock exchange releaseApril 4, 2024 at 4.00 pm EESTResolutions of Outokumpu’s Annual General Meeting 2024 Outokumpu’s Annual General Meeting 2024 was held today on April 4, 2024 at the Clarion Hotel Helsinki in Helsinki, Finland. The Annual General Meeting supported all of the proposals by the Board of Directors and the Shareholders’ Nomination Board. The Annual General Meeting approved the financial statements and discharged the Board of Directors and the CEO of the company from liability for the financial year 2023. The Annual General Meeting decided that a

Conference call interim report

Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1, 2024. The presentation will be held in English.Time: Thursday 18 April, 2024 at 10.00 a.m. CET. To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group 

Henrik Ehrnrooth to continue as the Chair of the Board of Directors of UPM-Kymmene Corporation

UPM-Kymmene Corporation        Stock Exchange Release (Other information disclosed according to the rules of the Exchange)        4 April 2024 at 15:50 EEST Henrik Ehrnrooth to continue as the Chair of the Board of Directors of UPM-Kymmene Corporation Henrik Ehrnrooth was elected as Chair, and Kim Wahl as Deputy Chair of the Board of Directors of UPM-Kymmene Corporation at the Board of Directors’ constitutive meeting that took place today following the Annual General Meeting. In addition, the Board of Directors elected the chairs and other members to the Board committees from among

Enhancing Isku’s furniture production with a new biobased, non-staining adhesive

Isku has switched to Kiilto’s biobased, pH-neutral Kiilto Pro WRX 3070 adhesive in its furniture production. The new adhesive also has very low formaldehyde content. The change of adhesive has improved the quality, productivity and safety of Isku’s production process.Finnish furniture manufacturer Isku  recently started using Kiilto’s biobased Kiilto Pro WRX 3070  adhesive, developed specifically for the furniture industry. D3 class PVAc adhesives are used in the wood manufacturing industry for products such as doors,

Medivir 2023 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company’s website: www.medivir.com. In the fall of 2023, very promising data from the ongoing phase 1b/2a study with Medivir's spearhead project fostrox in combination with Lenvima[®] were presented. The combination has shown continued improved clinical benefit in patients with advanced primary liver cancer (HCC) and at ASCO-GI in January 2024, data were presented showing further increases in the proportion of patients achieving a clinically relevant reduction

Borr Drilling Limited - Contracting update

Borr Drilling Limited (the “Company”) (NYSE and OSE: “BORR”) has today received a notice of temporary suspension of operations for its rig “Arabia I”, operating in Saudi Arabia. The temporary suspension will be for a period of up to 12 months, and is expected to commence in the second quarter. The Company intends to seek alternative engagement for the rig while on suspension. Hamilton, Bermuda 4 April 2024 Forward looking statements This press release includes forward looking statements, which do not reflect historical facts and may be identified by words such as “expected”, “

The Nomination Committee announces its proposal for changes to the Board of Directors

The Nomination Committee of Kebni AB (publ) has put forward the following proposal for changes to the Board of Directors ahead of the Annual General Meeting, which will be held on May 16[th], 2024. The Nomination Committee has communicated the following proposal to the company, which the company hereby discloses. For the Board of Directors, the re-election of Jan Wäreby and Magnus Edman are proposed, along with the new election of Anders Persson, Anna-Karin Stenberg and Martin Elovsson. Anders Persson is proposed to be elected as the Chairman of the Board.  More information about

CS MEDICA A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS MEDICA is now set to launch its CANNASEN® Protective Nasal Gel for sale in the first Asian market.CS MEDICA announces the Malaysian approval of CANNASEN® Protective Nasal Gel. This important approval not only brings an innovative product to the market but symbolizes CS MEDICA's breakthrough in overcoming the complex regulatory barriers in Asia.  A Milestone for CS MEDICA Lone Henriksen, CEO of CS MEDICA, comments, "This approval is a monumental achievement for CS MEDICA. Our journey to this point has been marked by a commitment to our goals and a persistent determination to

ITAB signs agreement for delivery of loss prevention solutions to leading European grocery chain

ITAB Group (“ITAB”) has signed an agreement with a leading grocery chain for the delivery of entrance & exit gates with integrated software aimed at improving loss prevention in their stores across Europe. The implementation will begin in May 2024 and the total value of the contract is estimated for at least MEUR 8 over three years.Together with the customer, a Dutch based leading grocery chain with global footprint, ITAB has developed tailored loss prevention solutions for the customer’s stores with the aim of reducing the risk for theft and shrinkage. Under the contract, ITAB will deliver

Decisions of UPM-Kymmene Corporation’s Annual General Meeting

UPM-Kymmene Corporation        Stock Exchange Release (Decisions of general meeting)        4 April 2024 at 14:50 EEST Decisions of UPM-Kymmene Corporation’s Annual General Meeting The Annual General Meeting (AGM) of UPM-Kymmene Corporation took place in Helsinki, Finland, today, 4 April 2024.  The AGM adopted the Company’s Financial Statements 2023 and resolved on a dividend of EUR 1.50 per share for the year 2023. The dividend is paid in two instalments. The AGM adopted the Remuneration Report and Remuneration Policy for governing bodies, elected the auditor for the financial

Heimstaden 2024 Annual General Meeting

Heimstaden AB has today held its Annual General Meeting 2024 and mainly resolved upon the following in accordance with the presented proposals: · Adoption of the 2023 Annual, Governance, and Sustainability Report and the proposal for the allocation of the Company’s result and dividend · Granted discharge from liability to the current and former Board Members, and the CEO, for their management in 2023 · Re-election of Ivar Tollefsen as Chairperson and John Giverholt and Fredrik Reinfeldt as Board Members. Bente Landsnes elected as new Board Member  · Adoption of the proposal

Safeture's Tech Elevates SEPAR International's Security Services

Safeture AB has signed a three-year partnership agreement with SEPAR International Ltd, a leading security advisory and risk mitigation service provider. SEPAR International Ltd specializes in risk management, training, and global operations. It provides creative resolutions to solve complex problems in challenging environments.SEPAR International Ltd has extensive experience in training and supporting the media and the humanitarian sector in hostile environments. It leads by example and is recognized by clients as trusted, supportive, and valued.   The company provides accurate and

Publishing of Valmet's Interim Review January – March 2024 on April 24, 2024

Publishing of Valmet's Interim Review January – March 2024 on April 24, 2024   Valmet Oyj’s press release on April 4, 2024 at 2:00 p.m. EEST    Valmet’s Interim Review January – March 2024 will be published on Wednesday, April 24, 2024, at approximately 1:00 p.m. Finnish time (EEST). The stock exchange release and presentation material in English and in Finnish will be available at that time on Valmet's website at www.valmet.com/investors.   Webcast   Valmet will arrange a news conference in English as a live webcast at https://valmet.videosync.fi/q1-2024 on

Decisions of Wulff Group Plc’s Annual General Meeting on April 4, 2024

STOCK EXCHANGE RELEASE | APRIL 4, 2024 AT 2.00 PM Wulff Group Plc’s Annual General Meeting held on April 4, 2024 decided to distribute a dividend of EUR 0.15 per share be paid for the financial year 2023. The dividend will be paid in two instalments. The record date of the first instalment of EUR 0.08 per share will be April 8, 2024 and the payment date will be April 15, 2024. The record date of the second instalment of the dividend of EUR 0.07 per share will be October 7, 2024 and the payment date will be October 14, 2024. The Annual General Meeting authorised the Board of Directors to

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 CEST at Helio GT30, Grev Turegatan 30, Stockholm, Sweden. Shareholders can participate in the annual general meeting by attending the venue in person or by voting in advance (postal voting). Right to participate in the annual general meeting and notice of participation Participation in the annual general meeting at the venueA shareholder who wishes to participate in the annual general

Basis swap and AT1 impact Q1 2024

In the first quarter of 2024, the DNB Group will recognise a negative mark-to-market effect of NOK 240 million from basis swaps connected to funding. Furthermore, a positive effect of NOK 543 million from the USD and SEK Additional Tier 1 capital will also be recognised. The effects will appear under Net gains on financial instruments at fair value in our financial statement. For further information, please contact:Rune Helland, Head of Investor Relations, tel.: (+47) 23 26 84 00 / (+47) 97 71 32 50

There are no items matching the current filter
There are no more items matching the current filter
Back to top